ALS symptom progression brings challenges, but for columnist Dagmar Munn, the key to living well with the disease is to be ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ALS in the EU.

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...

Rozebalamin, an ultra-high dose vitamin B12 treatment, was approved in Japan to slow disease progression in people with ALS.

A Texas Children’s Hospital investigator won a $2.4 million NIH grant for ALS and other neurodegenerative disease research.

After her late husband's diagnosis anniversary, columnist Juliet Taylor reflects on how grief became a heavy burden and a ...

The Scott-Morgan Foundation is launching a joint initiative that aims to use AI technologies to help improve communication ...

People with ALS can benefit from voice-generating artificial intelligence, improving their quality of life, columnist Kristin Neva writes.

Muscular Dystrophy Association (MDA) is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and over 300 related neuromuscular conditions.

A treatment candidate from Revalesio named RNS60 protected motor neurons from damage in a mouse model of amyotrophic lateral sclerosis (ALS) linked with accumulating toxic TDP-43 protein clumps. It ...

NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating amyotrophic lateral sclerosis (ALS), based on positive findings ...